→ First look – Porter Stansberry’s Next Big Prediction (From Porter & Company)

Johnson & Johnson (NYSE:JNJ – Get Rating) – Research analysts at SVB Leerink dropped their Q4 2022 earnings per share (EPS) estimates for Johnson & Johnson in a report issued on Friday, January 20th. SVB Leerink analyst D. Risinger now anticipates that the company will post earnings per share of $2.22 for the quarter, down from their previous forecast of $2.24. SVB Leerink currently has a “Outperform” rating and a $186.00 target price on the stock. The consensus estimate for Johnson & Johnson’s current full- year earnings is $10.04 per share. SVB Leerink also issued estimates for Johnson & Johnson’s Q1 2023 earnings at $2.47 EPS, Q2 2023 earnings at $2.49 EPS, Q3 2023 earnings at $2.59 EPS, Q4 2023 earnings at $2.34 EPS, FY2023 earnings at $9.88 EPS, FY2024 earnings at $10.36 EPS, FY2025 earnings at $10.77 EPS and FY2026 earnings at $11.34 EPS.

Several other analysts have also recently issued reports on JNJ. Atlantic Securities reduced their price objective on Johnson & Johnson from $165.00 to $160.00 and set a “neutral” rating on the stock in a research note on Wednesday, October 19th. Morgan Stanley price reduced the objective on Johnson & Johnson from $178.00 to $176.00 and set an “equal weight” rating on the stock in a research note on Tuesday, December 6th. Raymond James reduced their price objective on Johnson & Johnson from $192.00 to $185.00 and set an “outperform” rating on the stock in a research note on Wednesday, October 19th. Citigroup increased their price objective on Johnson & Johnson from $198.00 to $205.00 and gave the company a “buy” rating in a research note on Monday, December 12th. Finally, Barclays initiated coverage on Johnson & Johnson in a research note on Monday, October 17th. They issued an “equal weight” rating and a $175.00 price objective on the stock. Seven equities research analysts have rat ed the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $181.75.

Johnson & Johnson Trading Down 0.5%

JNJ opened at $168.74 on Monday. Johnson & Johnson has a 52 week low of $155.72 and a 52 week high of $186.69. The business has a fifty day simple moving average of $176.14 and a 200-day simple moving average of $171.20. The fir a market cap of $441.17 billion, a P/E ratio of 23.50, a P/E/G ratio of 3.19 and a beta of 0.56. The company has a quick ratio of 1.18, a current ratio of 1.43 and a debt-to- equity ratio of 0.37.

Hedge Funds Weigh In On Johnson & Johnson

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. boosted its holdings in Johnson & Johnson by 1.2% in the 3rd quarter. Vanguard Group Inc. now owns 245,340,875 shares of the company valued’s at stock $40,078,885,000 after purchasing an additional 2,815,655 shares in the last quarter. State Street Corp boosted its holdings in Johnson & Johnson by 0.6% in the 3rd quarter. State Street Corp now owns 141,886,311 shares of the company’s stock valued at $23,178,548,000 after purchasing an additional 803,013 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in Johnson & Johnson by 3.3% in the 3rd quarter. Price T Rowe Associates Inc. MD now owns 25,428,626 shares of the company’s stock valued at $4,154,022,000 after purchase 8 shares in the last quarter. Legal & General Group Plc boosted its holdings in Johnson & Johnson by 2.3% in the 2nd quarter. Legal & General Group Plc now owns 18,839,914 shares of the company’s stock valued at $3,344,295,000 after purchasing an additional 421,779 shares in the last quarter. Finally, FMR LLC boosted its stake in shares of Johnson & Johnson by 20.8% during the 2nd quarter. FMR LLC now owns 18,725,049 shares of the company’s stock worth $3,323,883,000 after acquiring an additional 3,229,032 shares in the last quarter. Hedge funds and other institutional investors own 67.94% of the company’s stock.

Insider Transactions at Johnson & Johnson

In other news, CFO Joseph J. Wolk sold 14,781 shares of Johnson & Johnson stock in a transaction dated Tuesday, December 13th. The stock was sold at an average price of $179.60, for a total transaction of $2,654,667.60. Following the sale, the chief financial officer now owns 35,812 shares in the company, valued at $6,431,835.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, EVP resshaold3 Ashley Mcevoy, the 2 s firm’s stock in a transaction dated Wednesday, November 30th. The stock was sold at an average price of $175.47, for a total transaction of $12,865,986.81. Following the transaction, the executive vice president now owns 41,813 shares of the company’s stock, valued at $7,336,927.11. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Joseph J. Wolk sold 14,781 shares of the firm’s stock in a transaction dated Tue. sday, December 13th. The stock was sold at an average price of $179.60, for a total value of $2,654,667.60. Following the transaction, the chief financial officer now directly owns 35,812 shares in the company, valued at the approximate value of $6,43. can be found here. Over the last 90 days, insiders have sold 233,611 shares of company stock worth $40,960,735. Corporate insiders own 0.35% of the company’s stock.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 7th. Stockholders of record on Tuesday, February 21st will be given a dividend of $1.13 per share. This represents a $4.52 dividend on an annualized basis and a dividend of 2.68%. The ex-dividend date of this dividend is Friday, February 17th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 62.95%.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.

See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or out comments about this story [email protected].

Before you consider Johnson & Johnson, you’ll want to hear this.

MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before market the broader on… and Johnson & Johnson wasn’t on the list.

While Johnson & Johnson currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here